Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial

被引：1
|
作者：
Ludwig, Heinz [1 ]
Lechner, Daniel [2 ]
Gunsilius, Eberhard [3 ,4 ]
Fridrik, Michael [5 ]
Petzer, Andreas [6 ]
Kuehr, Thomas [7 ]
Knop, Stefan [8 ]
Schreder, Martin [9 ]
Weisel, Katja [10 ]
Rauch, Elisabeth [11 ]
Poenisch, Wolfram [12 ]
Greil, Richard [13 ]
Zojer, Niklas [14 ]
机构：
[1] Wilhelminen Canc Res Inst, Vienna, Austria
[2] Hosp Elisabethinen Linz, Internal Dept 1, Linz, Austria
[3] Med Univ, Innsbruck, Austria
[4] TILAK, Tumor Biol & Angiogenesis Lab, Innsbruck, Austria
[5] Gen Hosp Linz, Ctr Hematol & Med Oncol, Linz, Austria
[6] Krankenhaus Barmherzigen Schwestern Linz, Linz, Austria
[7] Acad Teaching Hosp Wels Grieskirchen, Wels, Austria
[8] Wurzburg Univ, Med Ctr, Wurzburg, Germany
[9] Univ Hosp Wurzburg, Wurzburg, Germany
[10] Univ Hosp Tuebingen, Tubingen, Germany
[11] Arbeitsgemeinschaft Med Tumortherapie, Salzburg, Austria
[12] Univ Leipzig, Dept Hematol, Leipzig, Germany
[13] Dept Med 3, Salzburg, Austria
[14] Wilhelminenspital Stadt Wien, Dept Med 1, Vienna, Austria
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-134
引用
收藏
页码：E75 / E75
页数：1
相关论文
共 50 条
  • [1] ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
    Ludwig, H.
    Poenisch, W.
    Knop, S.
    Schreder, M.
    Lechner, D.
    Hajek, R.
    Gunsilius, E.
    Fridrik, M.
    Petzer, A.
    Weisel, K.
    Rauch, E.
    Greil, R.
    Zojer, N.
    [J]. HAEMATOLOGICA, 2017, 102 : 110 - 110
  • [2] Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial
    Ludwig, Heinz
    Gunsilius, Eberhard
    Fridrik, Michael
    Greil, Richard
    Petzer, Andreas
    Kuehr, Thomas
    Knop, Stefan
    Schreder, Martin
    Rauch, Elisabeth
    Poenisch, Wolfram
    Zojer, Niklas
    [J]. BLOOD, 2016, 128 (22)
  • [3] A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Morphey, Ashley
    Johnson, Ralph J.
    Wesson, Emily T.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Weber, Donna M.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : E319 - E322
  • [4] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [5] Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
    Heinz Ludwig
    Wolfram Poenisch
    Stefan Knop
    Alexander Egle
    Martin Schreder
    Daniel Lechner
    Roman Hajek
    Eberhard Gunsilius
    Karl Jochen Krenosz
    Andreas Petzer
    Katja Weisel
    Dietger Niederwieser
    Hermann Einsele
    Wolfgang Willenbacher
    Thomas Melchardt
    Richard Greil
    Niklas Zojer
    [J]. British Journal of Cancer, 2019, 121 : 751 - 757
  • [6] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    [J]. Blood Cancer Journal, 9
  • [7] Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Orlowski, Robert Z.
    Alexanian, Raymond
    Wang, Michael
    Thomas, Sheeba
    Qazilbash, Muzaffar H.
    Parmar, Simrit
    Shah, Nina
    Bashir, Qaiser
    Popat, Uday
    Weber, Donna
    [J]. BLOOD, 2010, 116 (21) : 811 - 812
  • [8] Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis
    Bergin, Krystal
    Yuen, Flora
    Wallington-Beddoe, Craig Thomas
    Kalff, Anna
    Sirdesai, Shreerang
    Reynolds, John
    Spencer, Andrew
    [J]. BLOOD, 2018, 132
  • [9] Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
    Ludwig, Heinz
    Poenisch, Wolfram
    Knop, Stefan
    Egle, Alexander
    Schreder, Martin
    Lechner, Daniel
    Hajek, Roman
    Gunsilius, Eberhard
    Krenosz, Karl Jochen
    Petzer, Andreas
    Weisel, Katja
    Niederwieser, Dietger
    Einsele, Hermann
    Willenbacher, Wolfgang
    Melchardt, Thomas
    Greil, Richard
    Zojer, Niklas
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 751 - 757
  • [10] A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Reu, Frederic J.
    Valent, Jason
    Malek, Ehsan
    Sobecks, Ronald M.
    Faiman, Beth M.
    Hamilton, Kimberly
    Elberson, Jamie
    Fada, Sherry
    Liu, Hien K.
    Samaras, Christy
    Smith, Mitchell R.
    [J]. BLOOD, 2015, 126 (23)
12345